glp-1 timeline for weight loss of discovery and clinical development. (a) Key events in A timeline of GLP- 1

The development of insulin resistance is mainly postprandial and varies depending on the type of steroid used: intermediate-acting and long-acting GCs

Maintaining consistency with injection day and time helps establish predictable patterns

Unlike injectable GLP-1 therapies such as semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro), orforglipron is a daily oral medication

In most models of obesity, leptin concentrations are elevated, indicating the importance of leptin resistance in the pathogenesis of obesity

Semaglutide 2.4mg was linked to an average reduction of roughly 15% of body weight in the STEP 1 trial, while tirzepatide reached higher averages in the SURMOUNT-1 trial